Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Why investors are watching Neurizon Therapeutics (ASX: NUZ) ahead of FDA clearance for NUZ-001 Neurizon Therapeutics (ASX: NUZ) secures A$5m to fund ALS trial entry. Can NUZ-001 succeed in the HEALEY ALS Platform Trial and change the biotech landscape? byPallavi MadhirajuSeptember 18, 2025